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Abstract 18 
Pneumonia virus of mice (PVM) infection of BALB/c mice induces bronchiolitis leading to a 19 
fatal pneumonia in a dose-dependent manner, closely paralleling the development of severe 20 
disease during human respiratory syncytial virus infection in man, and is thus a recognised 21 
model in which to study the pathogenesis of pneumoviruses. This model system was used to 22 
investigate delivery of the internal structural proteins of PVM as a potential vaccination 23 
strategy to protect against pneumovirus disease. Replication-deficient recombinant human 24 
adenovirus serotype 5 (rAd5) vectors were constructed that expressed the M or N gene of 25 
PVM pathogenic strain J3666. Intranasal delivery of these rAd5 vectors gave protection 26 
against a lethal challenge dose of PVM in three different mouse strains, and protection 27 
lasted for at least 20 weeks post-immunisation. Whilst the PVM-specific antibody response 28 
in such animals was weak and inconsistent, rAd5N primed a strong PVM-specific CD8+ T cell 29 
response and, to a lesser extent, a CD4+ T cell response. These findings suggest that T-cell 30 
responses may be more important than serum IgG in the observed protection induced by 31 
rAd5N. 32 
 33 
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1. Introduction 36 
Viruses classified within the genus Pneumovirus include the human (HRSV) and bovine 37 
(BRSV) respiratory syncytial viruses and pneumonia virus of mice (PVM) [1]. HRSV is an 38 
important respiratory pathogen, causing approximately 30 million cases of acute lower 39 
respiratory tract disease in children under 5 annually, some 10% of which require 40 
hospitalization [2]. Most infants recover from a natural HRSV infection but some suffer a 41 
fatal outcome [3]. Since long-term immunity is not established, infections reoccur 42 
throughout life [4] and in elderly or immunocompromised individuals, these can lead to 43 
serious complications [5].  44 
An early clinical trial of a formalin-inactivated HRSV vaccine led to exacerbation of disease 45 
on subsequent infection [6], associated with induction of low affinity, HRSV-specific 46 
antibodies [7], immune complex deposition and complement activation [8], and a Th2-47 
biased immune response [9]. Subsequently, many HRSV vaccine strategies have been 48 
investigated [10-14], however no clinically successful candidate has emerged. HRSV vaccine 49 
candidates are often investigated in mice, although very high challenge doses are required 50 
to give disease and even then, pathogenesis does not match that seen in severely affected 51 
human infants [15]. In contrast, low doses of PVM in its natural rodent host give clinical 52 
signs ranging from upper respiratory tract infection to fatal pneumonia [16] with 53 
pathogenesis that closely resembles severe HRSV disease in humans, making it an 54 
appropriate system for investigating pneumovirus pathogenesis and immune responses [17, 55 
18].  56 
HRSV vaccine strategies have focused on stimulating a strong systemic humoral response 57 
against the F and G glycoproteins [11, 19]. However, the natural response that resolves 58 
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pneumovirus infection is primarily mediated through CD8+ T-cells [20-24]. Recombinant 59 
adenoviruses (rAd) have been widely developed as vaccine candidates, including to deliver 60 
HRSV glycoproteins [13, 19, 25, 26], and typically elicit potent TH1-biased responses [27]. We 61 
therefore evaluated intranasal (i.n.) delivery of human rAd type 5 (rAd5) PVM recombinants 62 
in the mouse as a model for protection against pneumoviruses. We selected this route since 63 
it was superior to intramuscular (i.m) delivery in providing protection against either lethal 64 
influenza A virus challenge or HRSV replication in the lung [13, 28]; it is also now an 65 
established route for human vaccination [29]. We focused on the internal proteins M and N 66 
since they contain potent cytotoxic T-cell (CTL) epitopes in HRSV [30, 31] and H-2Db and H-67 
2Kb restricted CD8+ T cell epitopes in PVM [32, 33]. Furthermore, vaccinating calves with N 68 
protein vectors primed BRSV-specific T cells and conferred partial protection against BRSV 69 
challenge [34, 35] and mucosal immunisation of mice with HRSV N protein nanoparticles 70 
induced both specific antibody and T cell responses, and reduced HRSV pulmonary 71 
replication [36]. We show here that rAd5 containing the M or N gene of PVM is able to elicit 72 
long-term protection against lethal PVM infection in mice, correlating with the stimulation 73 
of PVM-specific CD4 and CD8 T-cell populations.  74 
2. Materials and methods 75 
2.1 Cell and virus culture 76 
A line of persistently PVM-infected cells (designated P2-2) was established by infecting BSC-77 
1 African green monkey kidney cells with PVM strain 15 at a multiplicity of infection of 0.01 78 
pfu per cell [37]. Following the initial appearance of cytopathic effect and loss of cells, 79 
medium was replaced every 2-3 days. Within 4 weeks, growth of persistently infected cells 80 
was detected and these were subsequently passaged as normal. P2-2 cells show PVM gene 81 
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expression by immunofluorescence and western blotting, and continuously produce 82 
infectious virus which is detectable in the growth medium. 83 
BS-C-1 cells, P2-2 cells and HEK293 cells were cultured in Glasgow minimal essential media 84 
(GMEM) plus 10% fetal bovine serum (FBS), GMEM plus 15% FBS or Dulbecco’s modified 85 
Eagle media (DMEM) plus 10% FBS respectively. PVM strain J3666 stocks were prepared and 86 
titrated in BS-C-1 cells as described previously [17]. Ad5 dl327 [38] was propagated in 87 
HEK293 cells cultured in DMEM plus 2% FBS. rAd5 stocks were amplified and titrated by 88 
plaque assay on HEK293 cells.  89 
2.2 Construction and characterization of recombinant Ad5 vectors 90 
rAd5 with E3 deletions and E1 genes replaced by transgenes were generated using the 91 
AdEasy™ Adenoviral Vector System (Stratagene) according to the manufacturer’s protocol. 92 
pShuttle-CMV plasmids, containing the M or N gene of PVM strain J3666 (Genbank 93 
AY743909) amplified by PCR from cDNAs using primers that included appropriate restriction 94 
enzyme sites, were used to generate rAd5M and rAd5N; the CMV promoters and transgene 95 
regions were verified by sequencing [39, 40]. A plasmid containing the Escherichia coli lacZ 96 
gene was used similarly to generate rAd5Z. Recombinant viruses were purified twice by 97 
caesium chloride density gradient centrifugation and dialysed against 20% glycerol in 98 
phosphate-buffered saline (PBS).  99 
2.3 Animal immunisation and processing  100 
Male and female BALB/c mice from the breeding colony at the University of Warwick were 101 
confirmed PVM-free by serology and used at 5-7 weeks old. C3H/He-mg animals were 102 
similarly sourced in-house [41]; 5-week old C57BL/6 mice were purchased from Charles 103 
River. Animal care was carried out in accordance with the UK Animal Scientific Procedures 104 
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Act 1986 and was approved by the University of Warwick Ethical Review Board. Mice were 105 
allocated to experimental groups with equal sex ratios, anaesthetised by intraperitoneal 106 
injection with ketamine (75 µg/g bodyweight) and xylazine (15 µg/g bodyweight) and 107 
inoculated i.n. with rAd doses in 50 µl PBS or PBS alone (control animals); repeat 108 
immunisations were at two week intervals. Animals were challenged i.n. with a lethal dose 109 
of 250 p.f.u. PVM strain J3666 in 50 µl PBS. Clinical signs were assessed as previously 110 
described [17] and bodyweight measured daily. Animals were sacrificed for welfare reasons, 111 
or at the end of the experiment, by cervical dislocation.  112 
2.4 ELISA 113 
Flat-bottom microtitre plates were coated overnight at 4 °C with 1 µg/ml of either purified 114 
Ad5 dl327, or P2-2 or BS-C-1 cell lysate (cell material harvested and fragmented by agitation 115 
with glass beads, then sonicated), then incubated for 2 h with blocking buffer (5% low fat 116 
dried milk in PBS containing 0.02% (w/v) Tween 20 (PBS-T)). Serum, or broncho-alveolar 117 
lavage (BAL) fluid obtained using 1.0 ml PBS per animal, was titrated in threefold dilutions 118 
after an initial 1:85 dilution in blocking buffer. Antibody was bound for 2 h at room-119 
temperature (r.t.), wells washed 3x with PBS-T, then horseradish peroxidise conjugated goat 120 
anti-mouse (Sigma) IgG –specific antibodies (Santa Cruz), diluted in blocking buffer, were 121 
added for 2 h at r.t. After 3x washing, 100 µl/well of 0.01 mg/ml 2,2’-azino-bis(3-122 
ethylbenzothiazoline-6-sulfonic acid) di-ammonium salt (ABTS) solution (Sigma) was added 123 
and absorbance measured at 405 nm using a Labsystems multiskan RC plate reader. 124 
Antibody levels were determined by linear regression analysis and values expressed as Log10 125 
endpoint titres. Statistical analysis was performed using the Mann Whitney U test with 126 
Prism software. 127 
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2.5 In vitro stimulation and analysis of PVM-specific lymphocytes 128 
Spleens or lungs in 2 ml PBS were passed through cell strainers, generating single-cell 129 
suspensions that were centrifuged at 1200 x g over Histopaque 1086 (Sigma, Poole, UK). 130 
Mononuclear cells at the interface were harvested, washed 3x in PBS and resuspended in 131 
RPMI 1640 medium (Life Technologies) containing 10% FBS, 0.1% β-mercaptoethanol, 10 132 
U/ml penicillin G and 10 µg/ml streptomycin sulfate (RPMI/10). Cells were re-stimulated in 133 
vitro with PVM-infected or mock-infected antigen-presenting cells (APCs) at a ratio of 10:1 134 
in 96-well U-bottom plates containing 200 μl of RPMI/10 further supplemented with 5 U/ml 135 
recombinant human IL-2 (Roche) and 10 µg/ml Brefeldin A (Calbiochem®) for 16 h at 37 oC. 136 
APCs were naïve spleen cells, either PVM-infected (1 p.f.u. /cell) or mock-infected with BS-C-137 
1 cell lysate for 90 min at 37 oC, irradiated (3000 rad) and washed. After re-stimulation, cells 138 
were surface stained with rat anti-mouse CD8α allophycocyanin or rat anti-mouse CD4 139 
phycoerythrin mAbs (BD Pharmingen). Intracellular staining used CytoFix/CytoPerm solution 140 
and Perm/Wash buffer according to the manufacturer’s instructions (BD Biosciences), and 141 
rat anti-mouse IFNγ-FITC (BD Biosciences). Cells were analysed on a FACSCalibur flow 142 
cytometer (BD Biosciences) and data analysed using CellQuest software.  143 
3. Results 144 
3.1 Immunisation with rAd5N or rAd5M protects mice against lethal PVM infection 145 
Expression of PVM M and N by rAd5 in cell culture was confirmed by immunofluorescence 146 
or Western blotting, respectively (data not shown).To evaluate protection by rAd5M, rAd5N 147 
or rAd5Z, mice were immunised i.n. on day 0 and day 14, then challenged on day 28 with a 148 
lethal dose of PVM and monitored for 2-3 weeks for clinical signs and bodyweight loss as 149 
previously described [17]. Animals receiving 106 p.f.u. of rAd5M or rAd5N developed severe 150 
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clinical signs of disease and significant weight loss upon challenge, similar to PBS mock-151 
immunised animals and were therefore not protected (data not shown). In contrast, all 152 
animals that received higher doses of rAd5M or rAd5N survived (Fig. 1). Animals receiving 153 
107 p.f.u. of either recombinant showed transient signs of infection and weight loss but 154 
made a complete recovery (Fig. 1A, B) whereas animals immunised with rAd5Z developed 155 
severe disease after challenge, equivalent to mock-immunised animals (Fig. 1C). Thus, at the 156 
107 p.f.u. dose, there was clear evidence of antigen-specific protection elicited by rAd5N and 157 
rAd5M. Survival data from these and subsequent experiments are summarised in Table 1. 158 
Animals receiving 108 p.f.u. of rAd5M or rAd5N remained healthy after challenge (Fig. 1A, B). 159 
Surprisingly however, 108 p.f.u. of control rAd5Z was also protective (Fig. 1C) although, in 160 
contrast to those receiving specific immunogen, rAd5Z animals developed some signs of 161 
illness. Thus the 108 p.f.u. dose protected mice effectively from lethal challenge but a 162 
significant component of that protection was antigen-nonspecific. This non-specific 163 
protection is clearly distinct from that previously shown to be produced by defective-164 
interfering (DI) influenza A virus against PVM. DI-based protection was undetectable 7 days 165 
post-administration of the protective virus and was interferon-dependent [41] whereas 166 
rAd5Z-based protection lasted for at least two weeks. Under our prime-boost protocol, and 167 
in contrast to its effect on PVM, 108 p.f.u. rAd5Z afforded no protection against influenza A 168 
virus (data not shown). 169 
To investigate single dose efficacy, mice were immunised and challenged with PVM six 170 
weeks later. Mice given 107 p.f.u. rAd5M or rAd5N developed transient weight loss and 171 
elevated clinical scores but made a full recovery, stabilising with bodyweights only a few 172 
percent from the starting weight (Fig. 2A) whilst rAd5Z gave no protection. These data 173 
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indicate that even a single i.n. dose of 107 p.f.u. of rAd5M or rAd5N elicits PVM-specific 174 
protection, although rAd5N was clearly more protective than rAd5M in this regimen. Similar 175 
to the two-dose regimen, one 108 p.f.u. dose of rAd5M or rAd5N gave full protection against 176 
disease whilst an equivalent single dose of rAd5Z also protected against lethal outcome, 177 
albeit with some signs of disease (Fig. 2B). 178 
Antigen-specific protection implied involvement of adaptive responses. Such responses vary 179 
in outbred populations because epitopes must be presented by highly polymorphic major 180 
histocompatibility complex (MHC) antigens. We therefore tested whether protection in 181 
BALB/c mice (MHC haplotype H2d) could be replicated in other mouse strains. C57BL/6 (H2b) 182 
and C3H/He-mg (H2k) mice, immunised with 107 p.f.u. rAd in a two-dose regime, were fully 183 
protected from PVM by rAd5N immunisation, as were C57BL/6 animals by rAd5M; in each 184 
case animals remained healthy following challenge (data not shown). rAd5M only partially 185 
protected C3H/He-mg animals with two of five succumbing during the challenge period, 186 
although one of these occurred without prior elevation in clinical score and so may not have 187 
been due to the challenge (data not shown). Thus, protection against lethal PVM infection 188 
by rAd PVM recombinants extends to multiple MHC haplotypes. 189 
Antigen-specific protection against PVM was observed at four and six weeks after the 190 
primary immunisation. To determine the duration of protection, BALB/c mice were 191 
challenged at 8, 11, 14 or 20 weeks after initial immunisation with 107 p.f.u. rAd in a two-192 
dose protocol (Fig. 3). Older animals are slightly less susceptible to PVM-induced disease 193 
[42] and this was reflected in the survival of some PBS mock-immunised animals. However, 194 
these control animals showed significantly greater weight loss and clinical scores than 195 
immunised animals following PVM challenge at any time-point. rAd5N or rAd5M protected 196 
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against lethal PVM challenge up to 20 weeks post-immunisation (Fig. 3A, B). Whilst rAd5M-197 
immunised animals showed some weight loss, particularly following prolonged delay 198 
between immunisation and challenge, this was transient and less severe than in rAd5Z-199 
immunised mice, which showed severe disease similar to the mock-immunised animals (Fig. 200 
3C). Thus, immunisation with 107 p.f.u. rAd5M or rAd5N can elicit long-lasting, antigen-201 
specific protection in mice against severe or lethal PVM disease.  202 
3.2 Immunisation with rAd5 PVM vectors induces a variable PVM-specific antibody response 203 
Vaccination with 107 p.f.u. rAd5N elicited no detectable anti-PVM serum IgG by day 14 (Fig. 204 
4A), and although a few mice showed some response at day 28, 2 weeks after the second 205 
immunisation, most still had no detectable PVM-specific antibody. Vaccination with 108 206 
p.f.u. rAd5N generated a greater anti-PVM IgG response, with one animal responding at day 207 
14 and an increased average titre among day 28 responding animals (Fig. 4B) although not 208 
all animals developed detectable antibody. This weak PVM-specific antibody response did 209 
not reflect an intrinsic problem in eliciting serum antibody responses by this vector and 210 
route of administration since robust anti-Ad5 serum antibody responses were induced by 211 
both 107 and 108 p.f.u. rAd (Fig. 4C, D). It was also not due to the assay failing to detect 212 
antibody directed against internal proteins of the virus, since the assay was highly effective 213 
in detecting binding of N-specific mAbs in comparison with either F-specific mAbs or 214 
polyclonal sera from PVM-infection mice (Fig. 4E). 215 
To determine whether anti-PVM IgG might develop or increase over a longer-term 216 
experiment, animals were immunised with 107 p.f.u. rAd in a two-dose regime and serum 217 
analysed by ELISA at weeks 8, 11, 14 and 20. Although some rAd5M-immunised animals 218 
possessed anti-PVM IgG at weeks 6, 8 and 11 (Fig. 5A), at no time point did any more than a 219 
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minority show a response. For rAd5N, only one animal developed detectable anti-PVM IgG 220 
by week 6 but the numbers responding and magnitude of response increased in weeks 8 221 
and 11 (Fig. 5B); again, only a minority showed a detectable response at any time point and 222 
anti-PVM IgG antibodies were no longer detectable by week 20. As expected, rAd5Z elicited 223 
no detectable anti-PVM IgG at any time (Fig. 5C). In contrast, all animals mounted a 224 
detectable anti-Ad5 response, confirming delivery of the immunogen (Fig. 5D-F). The 225 
absence of consistent anti-PVM antibody responses in the context of consistent protection 226 
from lethal PVM challenge suggested that an anti-PVM IgG response was not the primary 227 
mechanism of protection.  228 
3.3 Immunisation with rAd5N vector elicits a PVM-specific T-cell response 229 
rAd5N was selected to study T cell responses since it generated the more robust protection. 230 
Mice were immunised with 107 p.f.u in a two dose regimen and lymphocytes harvested for 231 
analysis on day 20. IFN-γ intracellular staining revealed that the majority of PVM-specific T-232 
cells induced by rAd5N in the spleen and lungs were CD4+ cells (0.2% CD4+ IFNγ+ in spleen 233 
and 0.08% CD4+IFNγ+ in lungs). In contrast, no PVM-specific CD8+ T-cells were observed 234 
(data not shown). However, 7 days after immunisation with three doses of 107 p.f.u. of 235 
rAd5N, 2 weeks apart, the majority of PVM-specific T-cells induced by rAd5N in the spleen 236 
were CD8+ T cells (9.2% CD8+IFNγ+ compared with 2.04% CD4+IFNγ+, Fig. 6). Notably, PVM-237 
specific T-cells were not detected in lung lymphocytes from these mice (data not shown); 238 
this may have been related to the high background IFNγ response observed in lung 239 
lymphocytes from these animals. As PVM-specific T cells were not elicited by rAd5Z (Fig. 6), 240 
the PVM-specific CD4+ and CD8+ splenocytes in rAd5N-immunised animals demonstrate that 241 
rAd5N induces a significant PVM-specific T-cell response. 242 
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4. Discussion 243 
Ad5 has a natural tropism for mucosal surfaces and is a potent stimulator of adaptive 244 
immunity [27, 43] making it an attractive candidate vector for recombinant pneumovirus 245 
vaccine development. We evaluated the properties of rAd5 vectors expressing PVM N or M 246 
proteins and found that i.n. immunisation with 107 p.f.u of either construct elicited 247 
protection against PVM lethal disease. This protection was maintained for 20 weeks in a 248 
two-dose regimen and for at least six weeks after a single immunisation. Protection also 249 
extended to mouse strains having three different MHC haplotypes. 250 
Only weak and inconsistent anti-PVM serum IgG responses were detected in immunised 251 
animals that were reliably protected against lethal PVM challenge, indicating that there was 252 
no correlation between the humoral response and protection. Notably, anti-PVM IgG had 253 
declined to undetectable levels by 20 weeks post immunisation yet all animals were still 254 
protected. Specific protection was not explained by priming for a rapid PVM-specific 255 
antibody response as there was no difference in specific IgG titres between rAd5N-256 
immunised and control vector or rAd5Z-immunised animals post-challenge (data not 257 
shown). PVM-specific antibody responses might be weak because PVM M and N proteins do 258 
not contain strong B-cell epitopes or because the route of administration could not elicit 259 
such responses. The latter is unlikely since rAd5 expressing HRSV antigens elicited good 260 
serum IgG responses when delivered by the i.n. route [13, 26] and our immunisations 261 
reliably elicited Ad5-specific IgG. We also considered whether our protocol might have 262 
elicited greater mucosal than serum antibody responses, however we did not detect any 263 
PVM-specific IgA in BAL fluid obtained from vaccinated mice. Therefore, whilst it remains 264 
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possible that rAd5N and rAd5M each elicited some form of antibody that our assays could 265 
not detect and which was the basis of protection, we consider this unlikely. 266 
In contrast to the weak PVM-specific antibody responses, rAd5N immunisation produced 267 
strong PVM-specific CD8+ and CD4+ T cell responses in the spleen. PVM-specific T cells are 268 
known to protect against challenge [23] and we propose that this cellular response is a 269 
major factor mediating specific protection in our study. Since rAd5N elicited protection 270 
against PVM challenge in three different mouse strains, this suggests that PVM N contains T-271 
cell epitopes that are recognised in multiple MHC backgrounds. 272 
Previous studies with rAd HRSV vaccine candidates have included vectors expressing the F 273 
protein [25, 26, 44, 45], G protein elements [13] or F, N and M2-1 proteins [46] which 274 
elicited strong anti-HRSV serum antibody and potent T-cell responses in mice. In contrast to 275 
PVM rAd5 studied here, vaccination with a chimpanzee rAd (PanAd3) expressing F, N and 276 
M2-1 caused accelerated onset of weight loss in mice following HRSV challenge, a difference 277 
most likely due to the high titre HRSV challenge inoculum encountering a strong CD8+ 278 
response induced by M2-1 [46]. However, whilst these studies demonstrate that various 279 
rAds and dosing regimens can inhibit HRSV replication in mouse lungs, the failure of even 280 
high-dose HRSV challenge of mice to fully replicate the pathogenesis of RSV infection in 281 
humans means the implications of these studies for protection of humans against HRSV 282 
disease are not clear. 283 
Whilst 107 p.f.u. rAd5N and rAd5M clearly elicited antigen-specific protection against PVM, 284 
significant non-specific protection against PVM disease was seen with a 10-fold higher dose 285 
rAd5Z, albeit less effective than equivalent doses of rAd5N or rAd5M. A similar finding of 286 
non-specific protection was reported previously in ferrets immunised with high dose rAd: 287 
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though having no effect on SARS coronavirus replication in the nose, control rAd reduced 288 
virus penetration into the lung and consequent pathology [47]. Many other studies of rAd 289 
immunisation have not included both empty rAd and non-immunised controls so any non-290 
specific protection would not have been detected. In one further study that incorporated 291 
both controls, non-specific protection in the airway was not seen after rAd delivery to mice 292 
i.m. [48]; this difference from our findings likely reflects the distinct immunisation and 293 
challenge target tissues preventing any non-specific local responses to the immunogen 294 
being protective. Further investigation is needed to understand the nature and scope of 295 
non-specific protection against respiratory infection following high-dose intranasal rAd 296 
delivery. 297 
One potential issue in extrapolating the present study to protection against HRSV in humans 298 
is that widespread immunity to Ad5 might compromise immunisation of infants with rAd5 299 
via maternal antibody [49]. However pre-existing circulating Ad5 antibody did not prevent a 300 
response to mucosally delivered rAd5-Ebola antigen that was sufficient to protect mice 301 
against lethal Ebolavirus challenge [50] so pre-existing antibody to rAd5 is not an absolute 302 
barrier to effective use. Alternatively, vectors based on either human Ad types of lower 303 
sero-prevalence, non-human Ads [45] or chimeric Ad5 vectors having substitutions in key 304 
antigenic regions [51] may be used, although these alternative Ad types may not share the 305 
strong immunogenicity of Ad5 [52]. 306 
In summary, we have shown that replication-deficient rAd5 vectors expressing internal 307 
antigens of PVM elicit robust protection against PVM disease in multiple mouse strains 308 
when delivered i.n. Protection can be generated with a single dose, and a two-dose regime 309 
provides long-term protection. As PVM pathogenesis in rodents is similar to HRSV infection 310 
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in humans, our findings of successful protection against disease in this model suggest that a 311 
similar strategy could be applied to protect against HRSV disease in humans. 312 
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Table 1 Survival data for animals challenged with PVM 483 
 484 
Immunogen BALB/c† C3H-He-mg C57BL/6 
107 p.f.u 
(x1) 
108 p.f.u. 
(x1) 
107 p.f.u. 
(x2) 
108 p.f.u. 
(x2) 
107 p.f.u. 
(x2) 
107 p.f.u. 
(x2) 
rAd5-N 6/6 5/5 3/3 6/6 5/5 5/5 
rAd5-M 3/6 6/6 5/6 6/6 3*/5 5/5 
rAd5-Z 1/6 6/6 0/6 4/4 2*/5 5*/5 
PBS 0/2 0/2 0/4 2*/4 0/4 0/4 
† Mice were inoculated i.n. with one (x1) or two (x2) doses of Ad5 immunogens, at day 0 485 
and 14, and were challenged i.n. at day 42 (x1) or day 28 (x2) with a lethal dose of PVM 486 
*Mice exhibited elevated clinical signs of disease 487 
  488 
 
 
24 
 
Figure Legends 489 
Fig. 1. rAd5M and rAd5N protect BALB/c mice from lethal PVM challenge. Mice were 490 
immunised i.n. at 0 and 14 days with either 107 or 108 p.f.u. of rAd5N (A), rAd5M (B), or 491 
rAd5Z (C) or mock-immunised with PBS as a control. All animals were challenged at 28 days 492 
with a lethal dose of PVM, and then weighed (left panels) and assessed for clinical signs of 493 
PVM disease (right panels) daily for the duration of the experiment. Weights are expressed 494 
as a proportion of the initial weight of the relevant group of mice with the weight on day 495 
zero taken as 100%. Clinical signs are expressed on a scale of 1 (healthy) to 5 (moribund) 496 
[17]. Results are the means from five mice for each group and are representative of two 497 
separate experiments. A single PBS control group was studied within each experiment and 498 
data from this group are reproduced in panels A – C for ease of comparison. 499 
 500 
Fig. 2. A single intranasal immunisation of rAd5M or rAd5N confers protection against PVM 501 
challenge. Mice were immunised with 107 p.f.u (A) or 108 p.f.u. (B) of either rAd5M, rAd5N 502 
or rAd5Z, or mock-immunised with PBS. Animals were challenged with PVM six weeks post 503 
immunisation and then weighed (left panels) and assessed for clinical signs of PVM disease 504 
(right panels) daily for the duration of the experiment. Dotted lines: mean weights or scores 505 
after the loss of one or more animals from the group. Other details as for Fig. 1. 506 
 507 
Fig. 3. Protection from lethal PVM challenge by rAd5M and rAd5N is long lasting. Mice were 508 
immunised i.n. at 0 and 14 days with 107 p.f.u doses of rAd5N (A), rAd5M (B) or rAd5Z (C) or 509 
mock-immunised with PBS, and groups of six immunised animals plus two mock-immunised 510 
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animals were challenged with a lethal dose of PVM at each time point. Following challenge, 511 
mice were weighed (left panels) and assessed for clinical signs of PVM disease (right panels) 512 
daily. The graphs for PBS mock-immunised animals were generated by taking an average of 513 
the data from the mice challenged at the various time points. Dotted lines: mean weights or 514 
scores after the loss of one or more animals from the group. A single experiment was 515 
conducted because of the numbers of animals involved. Other details as for Fig. 1. 516 
 517 
Fig. 4. Antibody titres in sera from rAd5N-immunised mice. Mice were immunised i.n. at 0 518 
and 14 days with either 107 p.f.u. (A, C) or 108 p.f.u (B, D) doses of rAd5N, rAd5Z or mock-519 
immunised with PBS as control. Sera from immunised animals were analysed for anti-PVM 520 
IgG responses (A, B) and anti-Ad IgG responses (C, D) by ELISA. Results are expressed as the 521 
geometric means of the Log10 endpoint titres, after correction of values for background, 522 
with the background taken as the mean values in the assay from PBS control animal sera. (E) 523 
Anti-N or anti-F monoclonal antibodies, or PVM-specific or control mouse sera, were 524 
titrated in the ELISA using either PVM antigen-containing (P2-2) or control (BS-C-1) cell 525 
lysate as antigens. 526 
 527 
Fig. 5. Longevity of antibody titres in sera of rAd5M and rAd5N immunised mice. Mice were 528 
immunised i.n. at 0 and 14 days with 107 p.f.u of rAd5M, rAd5N or rAd5Z or treated with PBS 529 
alone. Sera from immunised animals were analysed for anti-PVM IgG responses (A-C) and 530 
anti-Ad IgG responses (D-F) by ELISA. Antibody titres were calculated as for Fig. 4. 531 
 532 
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Fig. 6. Mucosal immunisation with rAd5N primes a PVM-specific T-cell response. Mice were 533 
immunised i.n. with 107 p.f.u of rAd5N or rAd5Z on days 0, 14 and 28 and spleens were 534 
harvested on day 35. Splenocytes from two mice from each group were pooled and 535 
stimulated in vitro with PVM or control cell lysate (BSC1) for 16 h, and responses were 536 
analysed by intracellular IFNγ staining of: (A) CD4+ and (B) CD8+ cells by flow cytometry. 537 
Frequencies of IFNγ+ cells are shown as a percentage of total CD4+ or CD8 T+ cell numbers in 538 
the upper right quadrant. Representative data of groups of 4 mice are shown. 539 
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